Therapy News and Research

RSS

Patients' and doctors' perceptions of osteoporosis management differ

Newly released findings of a multinational survey conducted on behalf of the International Osteoporosis Foundation (IOF) show clear disparities between patients' and doctors' perceptions of osteoporosis and its management.

12 Jan 2011

Scientists introduce DNA directly into cell nucleus using protein nanodisks

One of the challenges of gene therapy - a set of methodologies aimed at treating several nucleic acid diseases - is to assure that this material arrives directly to the nucleus of the cell without losing a substantial amount along the way and without producing any undesired side effects. With this aim, scientists experiment with the use of different types of vectors, molecules capable of transporting genetic material to the correct place.

12 Jan 2011

Epigenetic therapy holds promise for cancer management

Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC). The data is being published in the January 15, 2011 issue of Cancer Research.

12 Jan 2011

Neurology professor receives MFRF's 'See the Light' award for Tay-Sachs research

Miguel Sena-Esteves, PhD, associate professor of neurology at the University of Massachusetts Medical School, was presented with the annual "See the Light" award from the Mathew Forbes Romer Foundation in recognition of his work for leading the fight against children's genetic diseases of the brain.

12 Jan 2011

Genethon deploys Atempo Digital Archive to optimize biotherapy research data storage resources

Atempo, a leading provider of cross-platform data protection and archiving solutions, announced today that Genethon, a French non-profit biotherapy research center, has deployed Atempo Digital Archive, Atempo's advanced file archiving platform, to optimize its storage resources.

12 Jan 2011

Behavioral therapies help improve bladder control in men following prostate cancer surgery

Behavioral therapies such as pelvic-floor-muscle training and bladder-control strategies can reduce incontinence episodes by more than 50 percent in men following prostate-cancer surgery, according to new research from the Center for Aging at the University of Alabama at Birmingham and the Birmingham/Atlanta Veterans Affairs Geriatric Research, Education and Clinical Center.

12 Jan 2011

BPH, hair loss prevention drugs may produce adverse side effects in men

Researchers from Boston University School of Medicine, in collaboration with colleagues at Lahey Clinic and from Denmark and Germany, have found that 5a-reductase inhibitors, while improving urinary symptoms in patients with benign prostatic hyperplasia and possible hair loss prevention, produces significant adverse effects in some individuals including loss of libido, erectile dysfunction, ejaculatory dysfunction and potential depression.

12 Jan 2011

Emerging Healthcare enters option agreement with OceanBASIS

Emerging Healthcare Solutions, Inc. announced today that it has entered into an option agreement with OceanBASIS, a German company specializing in stem-cell and marine-collagen technologies and products.

12 Jan 2011

Proposed health research agency for UK

According to the Academy of Medical Sciences, a new body to regulate all health research in the UK should be established. The authorities suggest that the current regulatory system was dysfunctional and thus hampering medical advances and they blame red tape for the decline in the UK’s share of clinical research. The report suggests creating a Health Research Agency that would make approving projects quicker and cheaper. According to Health Secretary for England, Andrew Lansley, the government would consider how the recommendations could be implemented.

11 Jan 2011

SciClone initiates phase 2b study of SCV-O7 for oral mucositis

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of the first patient in the company's phase 2b clinical trial of SCV-07 for the prevention of oral mucositis (OM) -- a painful, debilitating, and costly toxicity caused by chemoradiotherapy regimens used to treat head and neck cancer.

11 Jan 2011

Stigma remains over Major Depressive Disorder

Despite there being 39.1 million people suffering from major depressive disorder (MDD) across the seven major markets, only one third of patients will seek help from a physician, finds latest research from independent analyst Datamonitor.

11 Jan 2011

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

Cyclacel Pharmaceuticals, Inc., today announced that it has opened enrollment of the SEAMLESS pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment of elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

11 Jan 2011

Positive results from Allovectin-7 Phase 3 trial in patients with metastatic melanoma

Vical Incorporated today announced a new publication summarizing results from the company's completed trials of Allovectin-7 including systemic responses and an excellent safety profile in patients with metastatic melanoma.

11 Jan 2011

First-ever global definition of lupus flare

The Lupus Foundation of America (LFA) spearheaded a four-year worldwide initiative with more than 120 lupus experts from 11 countries, the pharmaceutical and biotechnology industries, and federal agencies, which resulted in the first-ever global definition of a lupus flare. The development of Lupus Foundation of America Flare Definition (LFA-Flare) helps to overcome long-standing barriers to the development of new, safe, and more tolerable treatments for lupus.

11 Jan 2011

Study supports use of telomerase inhibitors for treatment of childhood cancers

Geron Corporation today announced the publication of preclinical data demonstrating that the company's telomerase inhibitor drug, imetelstat (GRN163L), currently in Phase 2 clinical trials, selectively targets cancer stem cells in pediatric tumors of neural origin.

11 Jan 2011

Bioheart announces primary focus on completing clinical evaluation of cell therapies for heart failure

Bioheart, Inc. announced today that Bioheart's primary focus is on completing clinical evaluation of its cell therapies for treating heart failure and related cardiac diseases.

11 Jan 2011

Cautionary note on measuring perceived pain in research

It is well known that pain is a highly subjective experience. We each have a pain threshold, but this can vary depending on distractions and mood. A paper in the International Journal of Behavioural and Healthcare Research offers a cautionary note on measuring perceived pain in research.

11 Jan 2011

Study identifies over 30 breast cancer gene targets involved in drug resistance to chemotherapy

A new study conducted by Josh LaBaer's research team in the Biodesign Institute at Arizona State University has pinpointed more than 30 breast cancer gene targets ---including several novel genes---that are involved in drug resistance to a leading chemotherapy treatment.

11 Jan 2011

European CE Mark approval for IntraPace's abiliti system

IntraPace, announced today that it has received European CE Mark approval for the abiliti system as a treatment for obesity. The CE Mark certifies that a product has met European Union requirements for commercial marketing in Europe.

11 Jan 2011

DAPT shows positive outcomes following treatment with OrbusNeich's Genous Stent

Data from patients who are considered high-risk due to underlying clinical conditions and who cannot be treated with drug eluting stents and the accompanying requirement of long-term dual antiplatelet therapy showed positive safety and short- and long-term clinical outcomes following treatment with OrbusNeich's Genous Stent, according to a study published online in EuroIntervention.

11 Jan 2011